EgyptResearch and clinical trials
87 children with Glanzmann thrombasthenia in Egypt: in more than half, the parents are related
In Egypt, 87 children with Glanzmann thrombasthenia from several centers were studied.
Blood and immune system diseases
An inherited bleeding disease in which blood platelets cannot come together to form a clot. Easy bruising and prolonged bleeding are seen from birth.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
Orphanet has a guideline for emergency doctors for this disease (language: French, Italian). See on Orphanet
This page is translated from the Turkish original.
This disease is followed through the “Blood and immune system diseases” group.
Platelets are tiny blood cells that stick to each other to stop bleeding. To do this, they have a special receptor protein on their surface. In this disease, that protein is missing or faulty. The platelet count is usually normal, but the cells cannot clump together. This is why bleeding lasts a long time.
How severe the bleeding is varies greatly from person to person, even within the same family. Spontaneous bleeding tends to decrease with age.
The platelet count is usually normal, but the bleeding time is long. Platelet clumping tests give abnormal results. The definite diagnosis is made with a special blood test that shows the receptor protein is missing. A genetic test can find the gene change that causes the disease.
Platelet transfusions are given when there is bleeding or before surgery. Medicines that stop a clot from breaking down too early are also used. If platelet transfusions do not work, an approved clotting factor treatment can be given. Hormone treatment helps with heavy menstrual bleeding. Regular dental care is important. Some people with severe disease have been cured with a stem cell transplant. The doctor who follows the disease decides which treatment is suitable.
The disease is passed on through recessive inheritance. The mother and father are carriers but usually have no symptoms. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. Girls and boys are affected equally. Recessive diseases may be more common in marriages between relatives. In genetic counselling, carrier testing and prenatal testing can be discussed.
Source: MedlinePlus Genetics: Glanzmann thrombasthenia · NORD: Glanzmann Thrombasthenia
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
We could not find a patient association specific to this disease.
For all rare diseases: Nadir Hastalıklar Federasyonu
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
EgyptResearch and clinical trials
In Egypt, 87 children with Glanzmann thrombasthenia from several centers were studied.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
Questions you can ask your doctor
ClinicalTrials.gov lists 3 active interventional studies for this disease. 2 are recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.
Selected records (studies with a site in Türkiye first):
Middle stage: the effect is being tested in a small group · Phase 2 · investigational (experimental)RecruitingNCT07136857
Middle stage: the effect is being tested in a small group · Phase 1 / Phase 2 · investigational (experimental)Active, not recruitingNCT06211634
Non-drug study (device, procedure, care, etc.)RecruitingNCT04119908
See all studies on ClinicalTrials.gov · Joining clinical trials
GlobalHealth policy
The International Pediatric Nephrology Association published its recommendations for diagnosing and treating atypical HUS in children.
GlobalResearch and clinical trials
Researchers re-examined the data from a large drug study.
TürkiyeResearch and clinical trials
A face-to-face survey was conducted with 104 PNH patients at 18 centers in Türkiye.
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:849
No separate ICD-11 code; WHO classifies this disease under: 3B62.0Y
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.